PD-L1 expression as a predictive biomarker in cancer immunotherapy

Cited by (1,001)

Items 901–1,000 of 1,001

1. Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
   Renata Colombo Bonadio, Maria Del Pilar Estevez-Diz · 2021 · Frontiers in Oncology
2. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
   Xiaoqiang Yin, Tongchui Wu, Yadong Lan, Wulin Yang · 2022 · Bioscience Reports
3. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer
   Haiping Zhang, Jun Wu, Zhifeng Liu, Jing-Wen Gao, Shu-Yu Li · 2022 · BioMed Research International
4. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting
   Shumei Kato, Bing Li, Jacob J. Adashek, Seong Won Cha, Daniella Bianchi-Frias, Dajun Qian, Lisa Kim, Tiffany W so, Marcus Mitchell, Naoki Kamei et al. · 2022 · OncoImmunology
5. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
   Xia Luo, Zhen Zhou, Xiaohui Zeng, Qiao Liu · 2022 · Frontiers in Pharmacology
6. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma
   Changwei Ke, Shejiao Dai, Fangshi Xu, Jia Yuan, Shuting Fan, Yang Chen, Longbao Yang, Yong Li · 2023 · BMC Cancer
7. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles
   Xialian Lai, Fengjiao Yao, Yacong An, Xundou Li, Xian‐Da Yang · 2023 · Molecules
8. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)
   Yanjun Wang, Shuo Yang, Li Wan, Wei Ling, Hao Hui Chen, Jinghua Wang · 2023 · International Journal of Oncology
9. Enhanced Electrochemical Characterization of the Immune Checkpoint Protein PD‐L1 using Aptamer‐Functionalized Magnetic Metal‐Organic Frameworks
   Ying Ma, Maoqiang Wu, Fayin Mo, Zuanguang Chen, Jing Lü, Duanping Sun · 2024 · Advanced Healthcare Materials
10. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective
    Danfeng Shi, Shuangyan Zhou, Xue‐Wei Liu, Chenxi Zhao, Huanxiang Liu, Xiaojun Yao · 2017 · Biochimica et Biophysica Acta (BBA) - General Subjects
11. Mismatch repair–deficient colorectal cancer: a model of immunogenic and immune cell–rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells
    Glen Le Flahec, Bogdan Badic, Briac Guibourg, Laurent Doucet, J.P. Bail, Pascale Marcorelles, Ulrike Schick, Arnaud Uguen · 2017 · Human Pathology
12. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature
    Prerna Guleria, Nuzhat Husain, Saumya Shukla, Sunil Kumar, Rajinder Parshad, Deepali Jain · 2018 · Annals of Diagnostic Pathology
13. A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
    Maarten Versteven, Johan M.J. Van den Bergh, Katrijn Broos, Fumihiro Fujiki, Diana Campillo-Davó, Hans De Reu, Soyoko Morimoto, Quentin Lecocq, Marleen Keyaerts, Zwi Nisan Berneman et al. · 2018 · Oncotarget
14. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages
    Angelica M. Silva, Pamela Andrea Villalobos, Michelle D. Williams, Roland L. Bassett, Callisia Nathelee Clarke, Jeffrey E. Lee, Naifa Lamki Busaidy, Nancy D. Perrier · 2018 · Surgery
15. Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study
    Irena T. Tan, Thomas E. Stinchcombe, Neal Ready, Jeffrey Crawford, Michael Datto, Rebecca J. Nagy, Richard Burnham Lanman, Lin Gu, Jeffrey Melson Clarke · 2019 · Translational Lung Cancer Research
16. Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget
    Xing Huang, Xiaozhen Zhang, Xueli Bai, Tingbo Liang · 2019 · Cellular and Molecular Immunology
17. Astragalus membranaceus–Derived Anti‐Programmed Death‐1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors
    Fu-Ling Chang, Keng‐Chang Tsai, Tsai-Yu Lin, Tz-Wen Yang, Yan-Ni Lo, Wang-Chuan Chen, Jui-Hsien Chang, Mei‐Kuang Lu, Chun‐Tang Chiou, Po-Hung Chen et al. · 2020 · BioMed Research International
18. Visible to mid IR: A library of multispectral diagnostic imaging
    Miae Won, Mingle Li, Hyeong Seok Kim, Pai Liu, Seyoung Koo, Subin Son, Jae Hong Seo, Jong Seung Kim · 2020 · Coordination Chemistry Reviews
19. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma
    Xiong Chen, Zhihuai Wang, Guifu Wang, Chi Zhang, Shengjie Jin, Guo‐Qing Jiang, Dousheng Bai · 2021 · Investigational New Drugs
20. GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma
    Yilin Yu, Zhiping Wang, Qunhao Zheng, Jiancheng Li · 2021 · Gene
21. PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
    Sagun Parakh, Ashan Musafer, S Paessler, Tom Witkowski, Connie S.N. Li Wai Suen, Candani S. A. Tutuka, Matteo Salvatore Carlino, Alexander Maxwell Menzies, Richard A. Scolyer, Jonathan Simon Cebon et al. · 2021 · Frontiers in Immunology
22. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
    Jiřı́ Novotný, John P. Cogswell, Hector David Inzunza, Christopher T. Harbison, Christine E. Horak, Steven D. Averbuch · 2016 · Annals of Oncology
23. Novel clinical trial designs emerging from the molecular reclassification of cancer
    Mina Nikanjam, Shumei Kato, Teresa Allen, Jason Keith Sicklick, Razelle Kurzrock · 2025 · CA A Cancer Journal for Clinicians
24. Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy
    Rosalyn M. Fey, Avery Billo, Terri Clister, Khang N.A. Doan, Elizabeth Berry, Deanne Tibbitts, Rajan P. Kulkarni · 2025 · Cancers
25. Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases
    Bastian Dislich, Alexandra Stein, Christian A. Seiler, Dino Kröll, Sabina Berezowska, Inti Zlobec, José A. Galván, Julia Slotta‐Huspenina, Axel Karl Walch, Rupert Langer · 2017 · Cancer Immunology Immunotherapy
26. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
    Milena Music, Ioannis Prassas, Eleftherios P. Diamandis · 2018 · Critical Reviews in Clinical Laboratory Sciences
27. Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
    Yue Song, Zhaoming Li, Weili Xue, Mingzhi Zhang · 2019 · Immunotherapy
28. Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach that predicts the clinical outcomes for cervical cancer
    Hong Chen, Bairong Xia, Tongsen Zheng, Ge Lou · 2019 · The International Journal of Biological Markers
29. Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival
    Yanmei Gao, Chunhe Yang, Ning He, Guodong Zhao, Jianfei Wang, Yadong Yang · 2020 · Frontiers in Oncology
30. Biomarkers for predicting the outcome of various cancer immunotherapies
    Leila Jafarzadeh, Mohammad Khakpoor-Koosheh, Hamed Mirzaei, Hamid Reza Mirzaei · 2020 · Critical Reviews in Oncology/Hematology
31. Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
    Ioannis Athanasios Vathiotis, Georgia Gomatou, Dimitrios J. Stravopodis, Nikolaos Konstantinos Syrigos · 2021 · International Journal of Molecular Sciences
32. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
    Ze Zhang, Wen‐Wen Zhang, Hongguang Wang, Bingyang Hu, Zhanbo Wang, Shichun Lu · 2021 · Frontiers in Immunology
33. PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
    Kazuo Okadome, Yoshifumi Baba, Noriko Yasuda‐Yoshihara, Daichi Nomoto, Taisuke Yagi, Tasuku Toihata, Katsuhiro Ogawa, Hiroshi Sawayama, Takatsugu Ishimoto, Masaaki Iwatsuki et al. · 2021 · Cancer Science
34. Novel emerging biomarkers to immunotherapy in kidney cancer
    Yasser M. A. Ged, Martin Henner Voss · 2021 · Therapeutic Advances in Medical Oncology
35. Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas—Looking Forward
    Alexandra C. Istl, Alessandro Gronchi · 2022 · Cancers
36. Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma
    Xao X. Tang, Hiroyuki Shimada, Naohiko Ikegaki · 2022 · Genes and Immunity
37. Interplay between the DNA Damage Response and Immunotherapy Response in Cancer
    Elizabeth Chun Yong Lee, Jessica Sook-Ting Kok, Bin Tean Teh, Kah Suan Lim · 2022 · International Journal of Molecular Sciences
38. Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80
    Tara Kang-Pettinger, Kayleigh Walker, Richard Brown, Richard H. Cowan, Helena Wright, Roberta Baravalle, Lorna C. Waters, Frederick W. Muskett, Matthew W. Bowler, Kovilen Sawmynaden et al. · 2022 · Journal of Biological Chemistry
39. Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
    Naoya Maekawa, Satoru Konnai, Yumie Asano, Takumi Otsuka, Eri Aoki, Hiroto Takeuchi, Yukinari Kato, Mika Kato Kaneko, Shinji Yamada, Yumiko Kagawa et al. · 2023 · PLoS ONE
40. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
    Xingyuan Cheng, Baoqing Chen, Sifen Wang, Jun Zhang, Jinhan Zhu, Mengzhong Liu, Shiliang Liu, Mian Xi · 2023 · The Oncologist
41. Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer
    Young Kwang Chae, Alan P. Pan, Andrew A. Davis, Nisha Anjali Mohindra, Maria Matsangou, Victoria Meucci Villaflor, Francis Joseph Giles · 2016 · Clinical Lung Cancer
42. Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry
    Amanda Chargin, Rian Morgan, Uma N. Sundram, Keith Shults, Ellen L. Tsay, Navneet P. Ratti, Bruce Kendrick Patterson · 2016 · Cancer Immunology Immunotherapy
43. Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology
    Habib Zarredar, Khalil Ansarin, Behzad Baradaran, Shiva Ahdi Khosroshahi, Safar Farajnia · 2018 · Cancer Investigation
44. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy
    Christine Megerdichian Parseghian, Madhavi Patnana, Priya Bhosale, Kenneth R. Hess, Ya‐Chen Tina Shih, Bumyang Kim, Scott Kopetz, Michael James Overman, Gauri Rajani Varadhachary, Milind M. Javle et al. · 2018 · Journal of Immunotherapy
45. Microbial biomarkers for immune checkpoint blockade therapy against cancer
    Keishi Adachi, Koji Tamada · 2018 · Journal of Gastroenterology
46. A gene expression-based immune signature for lung adenocarcinoma prognosis
    Lijuan Wang, Xizhi Luo, Chao Cheng, Christopher Ian Amos, Guoshuai Cai, Feifei Xiao · 2020 · Cancer Immunology Immunotherapy
47. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
    Katarzyna Tomela, Bernadeta Pietrzak, MARCIN T. SCHMIDT, Andrzej Adam Mackiewicz · 2020 · Life
48. Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
    Yue Fei, Jingwei Yu, Yang Li, Linyu Li, Shiyong Zhou, Tingting Zhang, Lanfang Li, Lihua Qiu, Bin Meng, Yi Pan et al. · 2020 · Journal of Cancer
49. Immune profiling and immunotherapeutic targets in pancreatic cancer
    Felicia L. Lenzo, Shumei Kato, Sarabjot Pabla, Paul DePietro, Mary Nesline, Jeffrey M. Conroy, Blake Burgher, Sean T. Glenn, Boris W. Kuvshinoff, Razelle Kurzrock et al. · 2021 · Annals of Translational Medicine
50. Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors
    Yusuke Takayama, Takashi Nakamura, Yuki Fukushiro, Shohei Mishima, Ken Masuda, Hiroyasu Shoda · 2021 · In Vivo
51. GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p
    Yao Li, Yan Zhai, Yuxuan Chen · 2021 · Journal of Ovarian Research
52. Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review)
    Guangshun Sun, Hanyuan Liu, Xuesong Shi, Pengyu Tan, Weiwei Tang, Xin Chen, Guoqiang Sun, Weijun Yang, Xiangyi Kong, Zhiying Zheng et al. · 2022 · International Journal of Oncology
53. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype
    Pascal Jézéquel, Hamza Lasla, Wilfried Gouraud, Agnès Basseville, Bertrand Michel, Jean‐Sébastien Frenel, Philippe Paul Juin, Fadoua Ben Azzouz, Mario Campone · 2024 · Breast Cancer
54. Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma
    Clara Martínez-Vila, Cristina Teixidó, Francisco Aya, Roberto Martín, Europa Azucena González‐Navarro, Llúcia Alós, Natalia Castrejón de Anta, Ana Maria Arance · 2025 · International Journal of Molecular Sciences
55. Advancing Immune and Cell-Based Therapies Through Imaging
    Vladimir Ponomarev · 2017 · Molecular Imaging and Biology
56. Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
    Xuanyi Wang, Zixuan Chai, Yinghong Li, Fei Long, Youjin Hao, Guizhi Pan, Mingwei Liu, Bo Li · 2020 · Genes
57. Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling
    Xianghong Zhou, Shi Qiu, Ling Nie, Di Jin, Kun Jin, Xiaonan Zheng, Lu Yang, Qiang Wei · 2020 · Frontiers in Oncology
58. A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer
    Jeong Uk Lim, Hye Seon Kang · 2021 · Annals of Translational Medicine
59. Combined Application of Bevacizumab and Pd-1 Blockade Displays Durable Treatment Effects by Increasing the Infiltration And Cytotoxic Function of Cd8 + T Cells in Lung Cancer
    Yanxia Liu, Tongmei Zhang, Lína Zhang, Cong Zhao, Zhiyun Zhang, Ziyu Wang, Meng Gu, Weiying Li, Baolan Li · 2022 · Immunotherapy
60. Structure of PD1 and its mechanism in the treatment of autoimmune diseases
    Mahdi Rezayi, Arezoo Hosseini · 2023 · Cell Biochemistry and Function
61. Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities
    Melinda Badenhorst, Albert D. Windhorst, Wissam Beaino · 2024 · Frontiers in Medicine
62. High-resolution spiral microfluidic channel integrated electrochemical device for isolation and detection of extracellular vesicles without lipoprotein contamination
    Yong-Hyun Kwon, Sun‐Young Park, Hairi Jiang, Nanjanagudu Ganesh Gurudatt, Kyungyeon Lee, Hyorim Jeong, Cheng X. Nie, Joonchul Shin, Kyung‐A Hyun, Hyo‐Il Jung · 2024 · Biosensors and Bioelectronics
63. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma
    Drew W. Pratt, Stefania Pittaluga, Maryknoll Palisoc, Patricia A. Fetsch, Liqiang Xi, Mark A. Raffeld, Mark R. Gilbert, Martha Quezado · 2017 · Journal of Neuropathology & Experimental Neurology
64. STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells
    Zhirui Nie, Wenwen Gao, Yan Zhang, Yuhe Hou, Jingxian Liu, Zhaoqiang Li, Wei Xue, Xidong Ye, An-min Jin · 2019 · Annals of Translational Medicine
65. Recent advances and application of PD-1 blockade in sarcoma
    Wenli Zuo, Lingdi Zhao · 2019 · OncoTargets and Therapy
66. Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
    Emanuelle M. Rizk, Angelina Seffens, Megan H. Trager, Michael R. Moore, Larisa J. Geskin, Robyn D. Gartrell, Winston Wong, Yvonne M. Saenger · 2019 · American Journal of Clinical Dermatology
67. Analysis of Cross-Association between mRNA Expression and RNAi Efficacy for Predictive Target Discovery in Colon Cancers
    Euna Jeong, Yejin Lee, Young‐Ju Kim, Ji-Eun Lee, Sukjoon Yoon · 2020 · Cancers
68. Tumor‐Infiltrating Immune Cells and PD‐L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma
    Xiao Wu, Xiurong Ke, Yangpeng Ni, Liping Kuang, Fan Zhang, Yusheng Lin, Wan‐Wan Lin, Xiao Xiong, Haihua Huang, Xianjie Lin et al. · 2020 · Journal of Immunology Research
69. Serum IL-5 and IFN-γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients
    Qiu Zhao, Yanzhi Bi, Huiting Sun, Min Xiao · 2021 · Disease Markers
70. Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes
    Hernani Gil-Julio, Francisco Perea, Antonio Rodríguez-Nicolás, José Manuel Cózar, Amanda Rocío González Ramírez, Ángel Concha, Federico Garrido, Natalia Aptsiauri, Francisco Ruiz‐Cabello · 2021 · International Journal of Molecular Sciences
71. Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers
    Mark Magdi Awad, Peter S. Hammerman · 2015 · Journal of Clinical Oncology
72. Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge
    Elizabeth Nally, Matthew R. Young, Vishwani Chauhan, Connor Wells, Bernadett Emma Szabados, Thomas B. Powles, Francesca Jackson‐Spence · 2024 · Cancer Management and Research
73. A universal immunohistochemistry analyzer for generalizing AI-driven assessment of immunohistochemistry across immunostains and cancer types
    Biagio Brattoli, Mohammad Mostafavi, Taebum Lee, Wonkyung Jung, Jeongun Ryu, Seonwook Park, Jongchan Park, Sérgio Pereira, Seung-Hwan Shin, Sangjoon Choi et al. · 2024 · npj Precision Oncology
74. Four Immune-Related Long Non-coding RNAs for Prognosis Prediction in Patients With Hepatocellular Carcinoma
    Muqi Li, Minni Liang, Tian Lan, Xiwen Wu, Wenxuan Xie, Tielong Wang, Zhitao Chen, Shunli Shen, Baogang Peng · 2020 · Frontiers in Molecular Biosciences
75. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines
    Karen Bräutigam, Elodie Kabore-Wolff, Ahmad Fawzi Hussain, Stephan Polack, Achim Rody, Lars Hanker, Frank Köster · 2021 · Journal of Cancer Research and Clinical Oncology
76. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
    Guus R. M. van den Heuvel, Leonie I. Kroeze, Marjolijn J. L. Ligtenberg, Katrien Grünberg, Erik A. M. Jansen, Daniel T. von Rhein, Richarda M. de Voer, Michel M. van den Heuvel · 2021 · Respiratory Research
77. Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes
    Jiaxi Yao, Shengwei Li, Xiaosheng Wang · 2022 · Frontiers in Cell and Developmental Biology
78. Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
    Natalia Krzyżanowska, Kamila Wojas‐Krawczyk, Janusz Milanowski, Paweł Adam Krawczyk · 2022 · International Journal of Molecular Sciences
79. RETRACTED ARTICLE: Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-β signalling pathway
    Yufei Dong, Dapeng Ding, Juebin Gu, Mingying Chen, Shijun Li · 2022 · Bioengineered · Retracted
80. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
    David A. Schoenfeld, Ross D. Merkin, Myrto K. Moutafi, Sandra Martinez, Adebowale Adeniran, Deepika Kumar, Lucia B. Jilaveanu, Michael E. Hurwitz, David L. Rimm, Harriet M. Kluger · 2022 · Frontiers in Oncology
81. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials
    Yao Lu, Wenkang Wang, Feng Wang · 2023 · Frontiers in Immunology
82. DDX18 drives tumor immune escape through transcription-activated STAT1 expression in pancreatic cancer
    Guoying Dong, Qin Wang, Mingxin Wen, Zhongkun Xia, Shujun Zhang, Wei Gao, Huaizhi Wang, Guangwei Wei, Yunshan Wang · 2023 · Oncogene
83. Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets
    Tatiana Vilela, Sofia Valente, Jorge Correia, Fernando Ferreira · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
84. The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
    Rui Zhao, Shu Yang, Wei Xu, Fengxian Jiang, Pancen Ran, Liying Pan, Jingliang Wang, Weihao Wang, Jing Zhao, Yahui Wang et al. · 2024 · Cancer Cell International
85. MiR-140-3p Downregulation in Association with PDL-1 Overexpression in Many Cancers: A Review from the Literature Using Predictive Bioinformatics Tools
    Νικόλαος Καποδίστριας, Catherine Bobori, Georgia Theocharopoulou · 2017 · Advances in experimental medicine and biology
86. Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy
    Mohamed H. M. Ali, Salman M. Toor, Fazle Rakib, Raghvendra Mall, Ehsan Ullah, Kamal H. Mroué, Prasanna R. Kolatkar, Khalid A. Al‐Saad, Eyad Elkord · 2019 · Vaccines
87. Immunoglobulin G-Based Steric Hindrance Assay for Protein Detection
    Yifan Dai, Wei Xu, Chung-Chiun Liu · 2019 · ACS Sensors
88. Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
    Manuel A. Silva, Nicolas Triltsch, S. Leis, Ivan Kanchev, Tze Heng Tan, Benjamine Van Peel, Marian Van Kerckhoven, Vanessa Deschoolmeester, Johannes Zimmermann · 2020 · The Journal of Pathology Clinical Research
89. Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking
    Jacob Kinggaard Lilja‐Fischer, Jesper Grau Eriksen, Jeanette Bæhr Georgsen, Thao T. Vo, Stine Rosenkilde Larsen, Jonathan D. Cheng, Michael Busch-Sørensen, Deepti Aurora-Garg, Torben Steiniche, Jens Overgaard · 2020 · Acta Oncologica
90. Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data
    Christopher J. D. Wallis, Keith A. Lawson, Mohit Butaney, Raj Satkunasivam, Jigarkumar R. Parikh, Stephen J. Freedland, Sandip Pravin Patel, Omid Hamid, Sumanta Kumar Pal, Zachary William Abraham Klaassen · 2020 · Japanese Journal of Clinical Oncology
91. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead
    Anjana A Pillai, Joseph C. Ahn, Laura Kulik · 2020 · The American Journal of Gastroenterology
92. The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”
    Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti · 2021 · Human Vaccines & Immunotherapeutics
93. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
    Dan Liu, Chunguang Ma, Ping Lu, Jifang Gong, Dingwei Ye, Siyang Wang, Peijian Peng, Yuxian Bai, Yuqin Song, Jianhua Chen et al. · 2021 · European Journal of Cancer
94. Expression, prognostic significance and therapeutic implications of PD‐L1 in gliomas
    Gayaththri Vimalathas, Bjarne Winther Kristensen · 2021 · Neuropathology and Applied Neurobiology
95. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
    Jan‐Malte Placke, Camille Soun, Jenny Bottek, Rudolf Alexander Herbst, Patrick Andres Maximilian Terheyden, Jochen Sven Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Christiane Pfeiffer et al. · 2021 · Frontiers in Oncology
96. Pembrolizumab in endometrial cancer: Where we stand now (Review)
    Aikaterini Aravantinou‐Fatorou, Αngeliki Andrikopoulou, Michael Liontos, Oraianthi Fiste, Vasiliki Epameinondas GEORGAKOPOULOU, Meletios Athanasios Dimopoulos, Maria Gavriatopoulou, Flora Zagouri · 2021 · Oncology Letters
97. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor
    Chuan Wang, Nur Syafinaz Zainal, San Jiun Chai, James Dickie, Chai Phei Gan, Natasha Zulaziz, Bryan Kit Weng Lye, Ruhcha V. Sutavani, Christian H. H. Ottensmeier, Emma Victoria King et al. · 2021 · Frontiers in Immunology
98. Multi-omics analysis reveals prognostic and therapeutic value of cuproptosis-related lncRNAs in oral squamous cell carcinoma
    Xiaoguang Li, Wenbin Zhou, Chang Zhu, Jiechen Liu, Zedong Ming, Cong Ma, Qing Li · 2022 · Frontiers in Genetics
99. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab
    Christian Brüggemann, Michael Constantin Kirchberger, Simone M. Goldinger, Benjamin Weide, A. Konrad, Michael Erdmann, Dirk Schadendorf, Roland S. Croner, Lukas Krähenbühl, Katharina Charlotte Kähler et al. · 2017 · Journal of Cancer Research and Clinical Oncology
100. Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review
     Sara Mucherino, Valentina Lorenzoni, Isotta Triulzi, Marzia Del Re, Valentina Orlando, Annalisa Capuano, Romano Danesi, Giuseppe Turchetti, Enrica Menditto · 2024 · Cancers